The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 13, 2022
Filed:
Dec. 19, 2018
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Université DE Rennes 1, Rennes, FR;
Enios Applications Private Limited Company, Kallithea Athens, GR;
Eric Chevet, Rennes, FR;
Aristotelis Chatziioannou, Kallithea Athens, GR;
INSERM, Paris, FR;
UNIVERSITÉ DE RENNES 1, Rennes, FR;
ENIOS APPLICATIONS PRIVATE LIMITED COMPANY, Kallithea Athens, GR;
Abstract
The present invention relates to a method of treatment and method of therapy selection for patient suffering from cancer. The inventors provide the first demonstration of a dual role of IRE1 downstream signaling in cancer. Indeed, the inventors demonstrate that the modulation of IRE1 signaling characteristics in GBM cells controls tumor aggressiveness. Furthermore, the inventors provide evidence supporting a novel concept where IRE-downstream signals play combined/integrated roles in cancer development, where XBP1s provides pro-tumoral signals, whereas RIDD of mRNA and miR17 rather elicits anti-tumoral features. Their data, obtained using established cell lines, patient tumor samples and primary GBM lines, depict a complex scenario where IRE1 signaling orchestrates distinct aspects of GBM biology. In particular, the invention relates to a method for predicting whether a subject will be eligible to a treatment with an IRE1 RNase inhibitor.